Puma Biotechnology enters into $50M at-the-market equity distribution agreement with Jefferies

PUMA BIOTECHNOLOGY, INC.

Up to $50M of common stock may be sold from time to time in ATM offerings through Jefferies LLC.
Jefferies receives 3% commission on gross proceeds; sales at prevailing market prices.
Company has no obligation to sell any shares under the agreement.
Shares offered under existing shelf registration statement (File No. 333-257687) effective July 13, 2021.
Agreement may remain effective until July 2024 unless earlier terminated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.